Research programme: cancer therapeutics - Echelon Biosciences/AMRI Hungary

Drug Profile

Research programme: cancer therapeutics - Echelon Biosciences/AMRI Hungary

Latest Information Update: 27 Aug 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AMRI Hungary; Echelon Biosciences
  • Class Small molecules
  • Mechanism of Action Phosphoric monoester hydrolase inhibitors; Phosphotransferase inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 02 May 2007 Albany Molecular Research is now called AMRI
  • 02 Feb 2005 Echelon Biosciences has acquired the rights to all intellectual property associated with its collaboration with ComGenex
  • 11 Jan 2005 Echelon Biosciences has been acquired by AEterna Zentaris
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top